详文均见于”最近进展”（除非另有说明）; 同一文章可能见于本节内不同分类
Full articles can be found under “Recent Progress” unless specified; same reports may be classified under different categories in this section
乳腺癌 Breast cancer
12/17/2022: 在氟维司群中加入 Capivasertib 治疗晚期激素受体阳性乳腺癌 (12/17/2022) Adding capivasertib to fulvestrant for advanced ER-positive breast cancer
12/11/2022: Camizestrant用于激素受体阳性/HER2 阴性乳腺癌 Camizestrantfor ER+/HER2- breast cancer
12/10/2022: T-DXd作为 HER2 阳性转移性乳腺癌患者的二线治疗优于 T-DM1 T-DXd is better than T-DM1 in second line therapy for metastatic HER-2 positive breast cancer
12/3/2022: Sacituzumab govitecan治疗雌激素受体阳性（ER+）/HER2 阴性 晚期乳腺癌患者Sacituzumab govitecan treating ER+/HER2- advanced breast cancer
10/9/2022: Elacestrant（口服选择性雌激素受体降解剂）治疗雌激素受体阳性, HER2 阴性晚期乳腺癌 Elacestrant (oral selective estrogen receptor degrader)in ER-positive, HER2-negative advanced breast cancer
8/21/2022: 贝伐单抗加内分泌维持治疗晚期或转移性激素受体阳性乳腺癌 Bevacizumab plus endocrine therapy as maintenance in advanced or metastatic ER-positive breast cancer
8/14/2022: FDA批准 fam-trastuzumab deruxtecan-nxki (Enhertu) 用于不可切除或转移性 HER2低表达的乳腺癌患者 FDA approves Enhertu for unresectable or metastatic HER2-low breast cancer
6/25/2022: Datopotamab deruxtecan (Dato-DXd) 加上 durvalumab治疗晚期三阴性乳腺癌Datopotamab deruxtecan plus durvalumab in locally advanced triple negative breast cancer
6/19/2022: Sacituzumab govitecan 治疗激素受体阳性/HER2 阴性晚期乳腺癌的III 期研究 A phase 3 study of sacituzumab govitecan in hormone receptor–positive/HER2-negative advanced breast cancer
6/18/2022: 曲妥珠单抗 deruxtecan用于HER2低表达的转移性乳腺癌Trastuzumab deruxtecan in HER2-low metastatic breast cancer
6/5/2022: [F-18]FES-PET 评估新诊断的转移性乳腺癌患者雌激素受体 [F-18]FES-PET evaluate estrogen receptor status in newly diagnosed metastatic breast cancer
5/8/2022: 抗体-药物偶联物治疗患有脑转移的HER2 阳性乳腺癌 Antibody-drug conjugate is promising in treating brain metastases in HER-2 positive breast cancer
4/10/2022: 70 岁以上乳腺癌患者的 Oncotype DX 复发评分和淋巴结状态 Oncotype DX scores and lymph node status in beast cancer women over 70
3/19/2022: FDA批准奥拉帕尼用于高危早期乳腺癌的辅助治疗 FDA approves Olaparib for adjuvant therapy of high-risk early breast cancer
2/20/2022: 一些 雌激素受体和淋巴结阳性的绝经后乳腺癌患者可免于化疗：RxPONDER 试验的更新 Some ER and lymph node-positive postmenopausal breast cancer patients can be spared with chemotherapy: update of RxPOINDER trial
2/12/2022: Eftilagimod Alpha 加紫杉醇治疗转移性乳腺癌 Eftilagimod Alpha treating metastatic breast cancer
1/30/2022: 荟萃分析: 蒽环类加紫杉烷可降低 10 年乳腺癌复发风险 Meta-analysis: anthracycline plus taxane reduces risk of breast cancer recurrence at 10 years
1/22/2022: 新辅助化疗后的残余癌症负担和乳腺癌的长期生存结果 Residual cancer burden after neoadjuvant therapy and long-term survival in breast cancer
1/15/2022: 术后 abemaciclib 联合内分泌治疗治疗高危早期乳腺癌：来自 monarchE 临床试验的最新疗效分析 Adjuvant abemaciclib in combination with endocrine therapy in high-risk early breast cancer: update from monarchE study
1/1/2022: 淋巴结阳性乳腺癌患者接受新辅助化疗和前哨淋巴结活检后的淋巴结复发率 Lymph node recurrence rate after neoadjuvant chemotherapy and sentinel lymph node biopsy alone in lymph node-positive breast cancer patients
肺癌 Lung Cancer
12/24/2022: 抗 TIGIT 抗体增强了IV 期高水平PD-L1的非小细胞肺癌的免疫治疗活性 Anti-TIGIT antibody increased activity of immunotherapy in ST IV NSCLC with high PD-L1 level
12/4/2022: FDA给于Sapanisertib快速通道用于NRF2突变的鳞状非小细胞肺癌 FDA has granted fast track status to Sapanisertib for pretreated NRF@-mutated squamous NSCLC
11/27/2022: 辅助阿特珠单抗有益于 PD-L1 表达 ≥ 50% 的非小细胞肺癌生存 Early data suggested survival benefit for adjuvant Atezolizumab in NSCLC with PD-L1 expression ≥ 50%
11/5/2022: 最近进展Recent Progress–>奥希替尼辅助治疗EGFR 突变 IB至 IIIA 期非小细胞肺癌的长期随访 Long-term follow-up in adjuvant Osimertinib therapy in EGFR-mutated stage IB-IIIA NSCLC
10/16/2022: 实际生活中Brigatinib 用于既往ALK-TKI 治疗过的非小细胞肺癌患者的数据 (10/16/2022) Brigatinib use in real life in NSCLC patients who received prior ALK-TKI
9/10/2022: 可切除非小细胞肺癌的新辅助化疗加免疫治疗 Neoadjuvant chemotherapy plus immunotherapy for resectable nonsmall cell lung cancer
8/20/2022: Pralsetinib 治疗RET 融合阳性癌症患者 Pralsetinib in RET fusion positive cancer
8/13/2022: FDA 批准capmatinib治疗转移性非小细胞肺癌 FDA approves capmatinib for metastatic NSCLC with MET mutation
8/7/2022: Adgrasib在 KRASG12C 突变非小细胞肺癌和脑转移患者中的活性Adgrasib used in KRASG12C-mutated NSCLC with brain metastases
7/30/2022: Ramucirumab加派姆单抗与标准护理相比治疗先前接受过免疫疗法的晚期非小细胞肺癌 Ramucirumab plus pembrolizumab versus standard of care in advanced NSCLC patients previously treated with immunotherapy
7/10/2022: 新型术前治疗可提高可切除的非小细胞肺癌的响应 Novel neoadjuvant therapy in resectable NSCLC
6/26/2022: Sitravatinib 用于免疫治疗后疾病进展的非小细胞肺癌 Sitravatinib in NSCLC patients who progressed after immunotherapy
5/14/2022: FDA 批准nivolumab（纳武单抗）和铂类化疗用于手术前早期非小细胞肺癌 FDA approved Nivolumab plus platinum-baed chemotherapy in neoadjuvant therapy for NSCLC
5/7/2022: 单独使用 Durvalumab 或联合 Oleclumab 或 Monalizumab 治疗不可切除的 III 期非小细胞肺癌 Durvalumab alone or plus Oleclumab or Monalizumab in unresectable ST III NSCLC
4/2/2022: Efti 与 Pembrolizumab 联合用在难以治疗二线转移性肺癌 Combination of Efti and pembrolizumab in second-line therapy for refractory nonsmall cell lung cancer
1/16/2022: Durvalumab 加 Tremelimumab 单独或联合放射治疗对先前 PD(L)-1 治疗无效的转移性非小细胞肺癌 Durvalumab plus Tremelimumab with or without radiation in NSCLC who progressed after prior anti-PD(L)-1 therapy
结直肠癌 Colorectal cancer
11/26/2022: 局部晚期错配修复缺陷（dMMR）型结肠癌的新辅助免疫检查点抑制治疗 Neoadjuvant immune checkpoint inhibition in locally advanced MMR-deficient colon cancer
10/1/2022: 新型免疫治疗组合用于微卫星稳定结直肠癌 Novel combination of immunotherapy in microsatellite-stable metastatic colorectal cancer
9/25/2022: 早期直肠癌的新辅助化疗, 切除和观察 Neoadjuvant chemotherapy, excision and observation for early-stage rectal cancer
8/26/2022: FOLFOXIRI + 贝伐单抗相比于 FOLFOX或FOLFIRI + 贝伐单抗在肝转移和右侧和/或 RAS/BRAFV600E 突变原发性结直肠组中的比较 FOLFOXIRI + bevacizumab versus FOLFOX/FOLFIRI + bevacizumab in patients with initially unresectable liver metastases and right-sided and/or RAS/BRAFV600E-mutated colorectal cancer
7/24/2022: 化疗加上帕尼单抗或贝伐单抗用于RAS 野生型转移性结直肠癌 Panitumumab versus bevacizumab plus chemotherapy in RAS wild-type colorectal cancer
4/3/2022: 肿瘤萌芽显示 III 期结肠癌的预后价值 Tumor budding demonstrates independent prognostic value in stage III colon cancer
3/26/2022: PD-1阻断剂单独用于错配修复缺陷 (dMMR) 局部晚期直肠癌 PD-1 inhibitor alone used in mismatch repair deficient locally advanced rectal cancer
胰腺癌 Pancreatic cancer
9/4/2022: 交替两种化疗可提高转移性胰腺癌的总体生存率 Sequencing therapy may improve survival in metastatic pancreatic cancer patients
6/4/2022: Nimotuzumab 治疗KRAS 野生型晚期胰腺癌 Nimotuzumab and gemcitabine in KRAS-wild type pancreatic cancer
肝细胞癌 Hepatocellular carcinoma
2/13/2022: 唾液微小 RNA作为肝细胞癌的生物标志物 Salivary miRNAs as non-invasive biomarkers of hepatocellular carcinoma
胃癌 Gastric cancer
9/24/2022: PD-L1 表达和其他变量与晚期胃食管癌免疫检查点抑制获益的关联 Association of PD-L1 expression and other variables with benefits from immune checkpoint inhibition in advanced gastroesophageal cancer
7/23/2022: 检查点抑制剂和靶向治疗作为晚期胃癌/胃食管交界处癌的一线治疗 Checkpoint inhibitors and target therapy as first-line therapy for advanced stage Gastric/GEJ cancer
5/15/2022: Trastuzumab deruxtecan 治疗 HER2 阳性晚期胃或胃食管结合部腺癌患者 Trastuzumab deruxtecan in HER-2-positive advanced gastric and GE junction adenocarcinoma
3/13/2022: 术前免疫疗法和辅助纳武利尤单抗治疗局部微卫星不稳定性高/错配修复缺陷胃/胃食管腺癌 Neoadjuvant nivolumab plus ipilimumab in localized microsatellite instability-high (MSI)/mismatch repair deficient (dMMR) gastroesophageal adenocarcinoma
2/26/2022: Pembrolizumab 加曲妥珠单抗和化疗治疗作为第一线治疗晚期 HER2 阳性胃癌Pembrolizumab plus Trastuzumab as first line therapy for advanced stage HER2-positive gastric cancer
胆道癌 Biliary tract cancer
1/23/2022: Durvalumab 联合吉西他滨和顺铂治疗晚期胆道癌患者 Durvalumab in combination with gemcitabine and cisplatin in advanced stage biliary tract cancer
子宫内膜癌 Endometrial cancer
10/23/2022: 头发矫直剂和其他美发产品的使用与子宫癌的发生 Hair straighteners and other hair products in relation to incidental uterine cancer
10/22/2022: 来曲唑和 Abemaciclib 用于雌激素受体阳性的复发性子宫内膜癌 Letrozole and abemaciclib in ER-positive recurrent endometrial cancer
1/9/2022: 派姆单抗治疗微卫星不稳定性高度晚期子宫内膜癌 Pembrolizumab in microsatellite instability–high advanced endometrial cancer
卵巢癌 Ovarian cancer
11/19/2022: FDA 批准 Mirvetuximab Soravtansine-gynx 用于治疗叶酸受体（FR）α 阳性耐铂类药的卵巢癌 FDA approved Mirvetuximab Soravtansine-gynx for patients with folate receptor alpha (FRα)-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer
7/9/2022: 晚期上皮性卵巢癌的一线化学免疫疗法相比于化疗的III 期双盲研究Front line phase III chemo-immunotherapy versus chemotherapy in advanced ovarian cancer
6/11/2022: Mirvetuximab Soravtansine 治疗耐铂类卵巢癌 Mirvetuximab Soravtansine in platinum-resistant ovarian cancer
5/28/2022: 腹腔内卡铂加静脉紫杉醇相比于静脉化疗治疗卵巢癌 Intraperitoneal versus intravenous carboplatin plus intravenous taxane as first-line therapy for ovarian cancer
4/30/2022: Durvalumab 和 tremelimumab 与一线新辅助化疗在晚期卵巢癌患者中的 II 期研究 Durvalumab and tremelimumab in combination with neoadjuvant chemotherapy in advanced ovarian cancer, a phase II study
2/19/2022: Ixabepilone加上贝伐单抗相比ixabepilone在铂类耐药/难治性卵巢癌中的活性Ixabepilone plus bevacizumab showed activity versus Ixabepilone in platinum-resistant or refractory ovarian cancer
前列腺癌 Prostate cancer
9/17/2022: MRI 引导聚焦超声局部治疗中危性前列腺癌 MRI-guided ultrasound focal therapy for patients with intermediate-risk prostate cancer
3/27/2022: FDA 批准Pluvicto用于治疗前列腺特异性膜抗原（PSMA）阳性转移性的去势抵抗性前列腺癌 FDA approves Pluvicto for PSMA-positive metastatic castration-resistant prostate cancer
2/27/2022: 奥拉帕尼加阿比特龙一线治疗转移性去势抵抗性前列腺癌 First line Olaparib plus Abiraterone in metastatic castration-resistant prostate cancer头颈部肿瘤 Head-and neck Cancer
膀胱癌 Bladder cancerHead and neck cancer
10/29/2022: 在复发性非肌肉浸润性膀胱癌中使用短期, 强化丝裂霉素 Shor-term, intensive chemoresection with mitomycin in recurrent nonmuscle invasive bladder cancer
4/17/2022: 一项II期临床试验治疗对BCG无反应的非浸润性膀胱癌 A phase II clinical trial in non-muscle-invasive bladder cancer unresponsive to BCG
头颈癌 Head and neck cancer
1/29/2022: Pepinemab 与 pembrolizumab联合用于复发性或转移性头颈癌患者 Combination of pepinemab and pembrolizumab in relapsed and recurrent metastatic head-and-neck cancer
神经内分泌肿瘤 Neuroendocrine Tumor
5/1/2022: Atezolizumab 和 Bevacizumab 治疗神经内分泌肿瘤 Treatment of neuroendocrine tumor with Atezolizumab and Bevacizumab
黑色素瘤 Melanoma
12/25/2022: Lifileucel 治疗免疫检查点抑制剂疾病进展后的晚期黑色素瘤 Lifileucel therapy in advanced melanoma after progression from check-point inhibitor
11/20/2022: PRAME×CD3 MC-F106C 在黑色素瘤中显示出作为 T 细胞受体驱动疗法的潜力 PRAME×CD3 MC-F106C showed potential as T-cell receptor-driven therapy in melanoma
5/22/2022: FDA 批准 Opdualag 用于不可切除或转移性黑色素瘤 FDA approves nivolumab/relatlimab-rmbw for unresectable or metastatic melanoma
3/12/2022: 高纤维饮食可能会改善黑色素瘤患者对免疫疗法的反应 A high-fiber diet may improve response to immunotherapy among melanoma patients
3/6/2022: 肠道微生物组与晚期黑色素瘤免疫检查点抑制剂响应的关联 Association of gut microbiome with response to immune checkpoint inhibitors in advanced melanoma
胸腺瘤和胸腺癌 Thymoma and Thymic cardinoma
10/8/2022: Avelumab 加axitinib治疗晚期 B3 型胸腺瘤和胸腺癌 Avelumab plus axitinib in treating advanced type B3 thymoma and thymic carcinoma
脑瘤 Brain tumor
9/11/2022: 巨细胞病毒疫苗治疗复发性胶质母细胞瘤 CMV vaccine in recurrent GBM
淋巴瘤 Lymphoma
9/3/2022: Epcoritamab 用于难以治疗的大 B 细胞淋巴瘤 Epcoritamab for refractory large B-cell lymphoma
7/2/2022: 与双特异性抗体复合的自然杀伤细胞治疗难治性淋巴瘤 Bridging bispecific antibody with NK cells in treating refractory lymphoma
6/12/2022: ZUMA-2 研究的三年随访: Brexucabtagene autoleucel (KTE-X19) 治疗复发/难治性套细胞淋巴瘤 Three-year follow-up of ZUMA-2 study: KTE-X19in relapsed/recurrent mantle cell lymphoma
5/29/2022: 一种双特异性抗体Glofitamab用于侵袭性淋巴瘤 A first-in-class bispecific antibody Glofitamab in aggressive lymphoma
4/9/2022: Axicabtagene ciloleucel 作为高危的大 B 细胞淋巴瘤（LBCL）的一线治疗 Axicabtagene ciloleucel as first-line therapy in high-risk large B cell lymphoma
3/20/2022: 循环肿瘤 DNA 分析用于中枢神经系统淋巴瘤的疾病检测 Circulating tumor DNA for non-invasive disease detection of CNS lymphoma
2/6/2022: Brentuximab vedotin组合提高了新诊断的晚期霍奇金淋巴瘤患者的总体生存率 Brentuximab vedotin combination improved overall survival in newly diagnosed advanced classic Hodgkin’s lymphoma
多发性骨髓瘤 Multiple myeloma
12/18/2022: Modakafusp Alfa 治疗多发性骨髓瘤 Modakafusp Alfa treating multiple myeloma
11/12/2022: 一种 B 细胞成熟抗原 × CD3 双特异性 T 细胞抗体首次用于复发/难治性多发性骨髓瘤人体I 期研究 A phase I first-in-human Study of a B-cell maturation antigen × CD3 bispecific T-cell Antibody, in relapsed/refractory multiple myeloma
10/15/2022: GPRC5D 靶向 CAR T 细胞用于骨髓瘤 GPRC5D targeted CAR T cell in heavily-treated multiple myeloma
10/2/2022: Teclistamab 治疗复发或难治性多发性骨髓瘤 Teclistamab used in relapsed or refractory multiple myeloma
8/27/2022: Elotuzumab 加泊马度胺和地塞米松治疗复发/难治性多发性骨髓瘤 Elotuzumab plus pomalidomide and dexamethasone for relapsed/refractory multiple myeloma
3/5/2022: FDA 批准 Ciltacabtagene Autoleucel 用于复发或难治性多发性骨髓瘤 FDA has approved Ciltacabtagene Autoleucel for relapsed and refractory multiple myeloma
髓样或淋巴样肿瘤 Myeloid and lymphoid tumors
5/21/2022: Pemigatinib 治疗伴有 FGFR1 重排的髓样或淋巴样肿瘤 Pemigatinib in patients with myeloid or lymphoid tumors with fibroblast growth factor receptor 1 (FGFR1) rearrangement
肿瘤生物学和治疗/诊断新进展 Tumor biology & New treatment/diagnosis progress
11/20/2022: PRAME×CD3 MC-F106C 在黑色素瘤中显示出作为 T 细胞受体驱动疗法的潜力 PRAME×CD3 MC-F106C showed potential as T-cell receptor-driven therapy in melanoma
8/20/2022: Pralsetinib 治疗RET 融合阳性癌症患者 Pralsetinib in RET fusion positive cancer
7/3/2022: 新发现的自我反应类先天性 T 细胞介导的癌症免疫 A newly discovered self-reactive innate-like T cells in cancer immunity
4/16/2022: 溶瘤病毒加载 CAR-T 细胞用以治疗实体癌肿瘤 Oncolytic virus-mediated CAR-T cells to treat solid tumors in mice
3/6/2022: 肠道微生物组与晚期黑色素瘤免疫检查点抑制剂响应的关联 Association of gut microbiome with response to immune checkpoint inhibitors in advanced melanoma
2/13/2022: 唾液微小 RNA作为肝细胞癌的生物标志物 Salivary miRNAs as non-invasive biomarkers of hepatocellular carcinoma
1/8/2022: HLA-A*03 与免疫检查点抑制剂治疗晚期癌症结果的关联 Association of HLA-A*03 and response to immune checkpoint inhibitor in cancer
1/2/2022: TEAD 抑制剂控制癌症生长和凋亡的功能 TEAD inhibitor controls cancer growth and apoptosis
预防和流行病学 Prevention and epidemiology
12/31/2022: CT 检查与儿童和年轻人的脑癌 Brain cancer after radiation exposure from CT examinations of children and young adults
11/13/2022: 摄入超加工的食品与结直肠癌风险的关联 Consumption of ultra-processed food linked to risk for colorectal cancer
11/6/2022: 结肠镜筛查对结直肠癌和相关死亡风险的影响 Effect of colonoscopy screening in relation to colorectal cancer incidence and related death
10/30/2022: 肠肝分流驱动的胆汁血症易患肝癌 Entero-hepatic shunt-driven cholemia predisposes to liver cancer
8/6/2022: 减肥手术与肥胖成人癌症风险和死亡率的关系 Association of bariatric surgery and risk of cancer and mortality in obese adults
7/31/2022: 全氟和多氟烷基物质在癌症发展和医疗保健成本中的作用 The role of per- and polyfluoroalkyl substances in cancer development and healthcare costs
2/5/2022: 常见的化学物质会增加雌二醇和孕酮合成并是潜在乳腺癌风险 Common chemicals that increase the synthesis of estradiol and progesterone are potential breast cancer risk factors